
Dr. Ashok Kumar Vaid is a senior Medical Oncologist and Haemato-Oncology specialist serving as Chairman of Medical Oncology, Haematology and Stem Cell Transplant at Medanta – The Medicity, Gurugram. With more than four decades of professional experience, he specialises in cancer treatment, blood disorders and stem cell transplantation.
His specialist medical education includes a DM in Medical Oncology from The Tamil Nadu Dr. M.G.R. Medical University, Chennai. His professional training and clinical background have supported his longstanding involvement in medical oncology and the treatment of complex cancer-related conditions.
His areas of expertise include leukaemias, lymphomas, solid tumours, blood cancers, bone marrow transplantation and stem cell transplantation. He is also associated with specialised treatment approaches involving cancer genomics, immunotherapy guidance and precision oncology.
Dr. Vaid has contributed to the development of stem cell transplantation services in North India and has played a significant role in establishing advanced transplant programmes. He has participated in numerous clinical research studies and received the Padma Shri Award in 2009 in recognition of his contributions to medicine.
Decades of expertise, proven results, and compassionate care — here is why patients from 50+ countries trust Dr. Ashok Kumar Vaid for Hematology & BMT treatment in India.
Over 20 years of dedicated clinical experience with 5,000+ procedures. One of the most trusted names in Hematology & BMT in India.
Dr. Ashok Kumar Vaid regularly treats patients from Africa, the Middle East, Central Asia, and Europe. Dedicated international patient support team available 24/7.
Practices at an internationally accredited hospital, ensuring patient safety standards that match the best hospitals in the USA and Europe.
World-class treatment at a fraction of USA, UK, or Australian prices. Transparent cost estimates provided before you travel.
Dr. Ashok Kumar Vaid holds postgraduate qualifications from premier Indian institutions and has advanced fellowship training in Hematology & BMT.
Every case is personally reviewed. Treatment plans are tailored, transparent, and discussed in detail before you make any decisions or travel arrangements.
AML, CML, CLL, ALL, Hodgkin & Non-Hodgkin Lymphoma, Multiple Myeloma — treated with chemotherapy, targeted therapy & BMT.
Autologous, allogeneic, and haplo-identical BMT for leukemia, lymphoma, aplastic anemia, and inherited blood disorders.
Cutting-edge immunotherapy using genetically modified T-cells for blood cancers that have relapsed after standard treatments.
Curative BMT for thalassemia major and sickle cell anemia in children and adults. Low-cost programs available across India.
Both immunosuppressive therapy and stem cell transplantation for severe and very severe aplastic anemia, including pediatric cases.
HSCT (Hematopoietic Stem Cell Transplant) for aggressive Multiple Sclerosis — a disease-modifying treatment available in India.
Expert care for childhood leukemia, thalassemia, ITP, and inherited bone marrow failure syndromes.
Diagnosis and treatment of bone marrow failure and pre-leukemia syndromes with modern protocols.
Comprehensive management of hemophilia A & B, Von Willebrand disease, platelet disorders, and coagulopathies.
The most complex and potentially curative form of BMT where stem cells come from a matched donor. Used for leukemia, aplastic anemia, and inherited blood disorders.
Patient's own stem cells are harvested and reinfused after high-dose chemotherapy. Used for multiple myeloma and relapsed lymphomas.
Revolutionary immunotherapy where the patient's own T-cells are genetically reprogrammed to attack cancer cells.
The only curative treatment for beta-thalassemia major and sickle cell disease through allogeneic stem cell transplantation.
Personalised chemotherapy and next-generation targeted agents for lymphoma, leukaemia, and related disorders.
Send your medical reports and get a personalised treatment plan. The team reviews cases from 50+ countries and responds within 24 hours.
Our team responds within 24 hours
Share your reports and receive a personalised treatment recommendation within 48 hours — at no cost.